 SOUTH SAN FRANCISCO, Calif., Jan. 05, 2021 GLOBE NEWSWIRE -- NGM Biopharmaceuticals, Inc. NGM Nasdaq: NGM, a biotechnology company focused on discovering and developing transformative therapeutics for patients, today announced the pricing of an underwritten public offering of 4,629,630 shares of its common stock at a price to the public of 27.00 per share. The aggregate gross proceeds from the offering are expected to be approximately 125.0 million, before deducting the underwriting discounts and commissions and estimated offering expenses payable by NGM. The offering is expected to close on or about January 8, 2021, subject to customary closing conditions. In connection with the offering, NGM has granted the underwriters a 30-day option to purchase up to an additional 694,444 shares of its common stock at the public offering price, less underwriting discounts and commissions. 